Is AN2 Therapeutics Stock a Good Investment?
AN2 Therapeutics Investment Advice | ANTX |
- Examine AN2 Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research AN2 Therapeutics' leadership team and their track record. Good management can help AN2 Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact AN2 Therapeutics' business and its evolving consumer preferences.
- Compare AN2 Therapeutics' performance and market position to its competitors. Analyze how AN2 Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if AN2 Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about AN2 Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in AN2 Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if AN2 Therapeutics is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine AN2 Therapeutics Stock
Researching AN2 Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 20.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.38. Some equities with similar Price to Book (P/B) outperform the market in the long run. AN2 Therapeutics recorded a loss per share of 1.99. The entity last dividend was issued on the 11th of January 2018.
To determine if AN2 Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AN2 Therapeutics' research are outlined below:
| AN2 Therapeutics generated a negative expected return over the last 90 days | |
| AN2 Therapeutics may become a speculative penny stock | |
| AN2 Therapeutics has high historical volatility and very poor performance | |
| AN2 Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (64.73 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| AN2 Therapeutics currently holds about 113.39 M in cash with (53.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| AN2 Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company shares are held by company insiders | |
| Latest headline from patch.com: Anthem Blue Cross Blue Shield, Stamford Health Announce New Agreement |
AN2 Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AN2 Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AN2 Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact AN2 Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises AN2 Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-11 | 2022-06-30 | -0.46 | -0.53 | -0.07 | 15 | ||
2023-05-11 | 2023-03-31 | -0.68 | -0.79 | -0.11 | 16 | ||
2024-08-14 | 2024-06-30 | -0.5925 | -0.48 | 0.1125 | 18 | ||
2024-03-28 | 2023-12-31 | -0.75 | -0.57 | 0.18 | 24 | ||
2022-05-10 | 2022-03-31 | -0.52 | -2.98 | -2.46 | 473 |
Know AN2 Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AN2 Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AN2 Therapeutics backward and forwards among themselves. AN2 Therapeutics' institutional investor refers to the entity that pools money to purchase AN2 Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Investments Llc | 2024-09-30 | 177.8 K | Two Sigma Advisers, Llc | 2024-09-30 | 120.9 K | Aldebaran Capital Llc | 2024-09-30 | 100.5 K | Marquette Asset Management Inc. | 2024-12-31 | 83.2 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 79.4 K | Schonfeld Strategic Advisors Llc | 2024-09-30 | 66.1 K | State Street Corp | 2024-09-30 | 60.3 K | Northern Trust Corp | 2024-09-30 | 32.6 K | Captrust Financial Advisors | 2024-09-30 | 28.7 K | Bml Capital Management Llc | 2024-12-31 | 5.7 M | Ra Capital Management, Llc | 2024-09-30 | 2 M |
AN2 Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 33.46 M.Market Cap |
|
AN2 Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.50) | (0.53) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.47) | (0.44) |
Determining AN2 Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if AN2 Therapeutics is a good buy. For example, gross profit margin measures AN2 Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of AN2 Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in AN2 Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AN2 Therapeutics. Check AN2 Therapeutics' Beneish M Score to see the likelihood of AN2 Therapeutics' management manipulating its earnings.
Evaluate AN2 Therapeutics' management efficiency
AN2 Therapeutics has return on total asset (ROA) of (0.3219) % which means that it has lost $0.3219 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5356) %, meaning that it created substantial loss on money invested by shareholders. AN2 Therapeutics' management efficiency ratios could be used to measure how well AN2 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.44 in 2025. Return On Capital Employed is likely to drop to -0.53 in 2025. At this time, AN2 Therapeutics' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 115.2 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 915.7 K in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.76 | 4.99 | |
| Tangible Book Value Per Share | 4.76 | 4.99 | |
| Enterprise Value Over EBITDA | 85.89 | 90.19 | |
| Price Book Value Ratio | 4.46 | 4.24 | |
| Enterprise Value Multiple | 85.89 | 90.19 | |
| Price Fair Value | 4.46 | 4.24 | |
| Enterprise Value | 421.1 M | 235.3 M |
Understanding the operational decisions made by AN2 Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.142 |
Basic technical analysis of AN2 Stock
As of the 18th of February 2025, AN2 Therapeutics owns the Market Risk Adjusted Performance of 0.0938, coefficient of variation of 3433.65, and Standard Deviation of 5.25. AN2 Therapeutics technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices.AN2 Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AN2 Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on AN2 Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AN2 Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand AN2 Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing AN2 Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0293 | |||
| Market Risk Adjusted Performance | 0.0938 | |||
| Mean Deviation | 3.4 | |||
| Semi Deviation | 2.87 | |||
| Downside Deviation | 3.16 | |||
| Coefficient Of Variation | 3433.65 | |||
| Standard Deviation | 5.25 | |||
| Variance | 27.56 | |||
| Information Ratio | 0.027 | |||
| Jensen Alpha | 0.141 | |||
| Total Risk Alpha | 0.1347 | |||
| Sortino Ratio | 0.0449 | |||
| Treynor Ratio | 0.0838 | |||
| Maximum Drawdown | 28.89 | |||
| Value At Risk | (5.38) | |||
| Potential Upside | 8.94 | |||
| Downside Variance | 9.97 | |||
| Semi Variance | 8.26 | |||
| Expected Short fall | (5.76) | |||
| Skewness | 2.5 | |||
| Kurtosis | 8.27 |
| Risk Adjusted Performance | 0.0293 | |||
| Market Risk Adjusted Performance | 0.0938 | |||
| Mean Deviation | 3.4 | |||
| Semi Deviation | 2.87 | |||
| Downside Deviation | 3.16 | |||
| Coefficient Of Variation | 3433.65 | |||
| Standard Deviation | 5.25 | |||
| Variance | 27.56 | |||
| Information Ratio | 0.027 | |||
| Jensen Alpha | 0.141 | |||
| Total Risk Alpha | 0.1347 | |||
| Sortino Ratio | 0.0449 | |||
| Treynor Ratio | 0.0838 | |||
| Maximum Drawdown | 28.89 | |||
| Value At Risk | (5.38) | |||
| Potential Upside | 8.94 | |||
| Downside Variance | 9.97 | |||
| Semi Variance | 8.26 | |||
| Expected Short fall | (5.76) | |||
| Skewness | 2.5 | |||
| Kurtosis | 8.27 |
Consider AN2 Therapeutics' intraday indicators
AN2 Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of AN2 Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.1 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.14 | |||
| Day Typical Price | 1.16 | |||
| Market Facilitation Index | 0.12 | |||
| Price Action Indicator | 0.06 | |||
| Relative Strength Index | 42.83 |
AN2 Stock media impact
Far too much social signal, news, headlines, and media speculation about AN2 Therapeutics that are available to investors today. That information is available publicly through AN2 media outlets and privately through word of mouth or via AN2 internal channels. However, regardless of the origin, that massive amount of AN2 data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of AN2 Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of AN2 Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to AN2 Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive AN2 Therapeutics alpha.
AN2 Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards AN2 Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
AN2 Therapeutics Corporate Management
| MBA BS | Chief Officer | Profile | |
| Vince Hernandez | Senior Chemistry | Profile | |
| Eric Easom | CEO, Cofounder | Profile | |
| Michael Alley | CoFounder Biology | Profile | |
| Stephen Prior | Chief Officer | Profile | |
| Paul MD | Chief Officer | Profile |
Already Invested in AN2 Therapeutics?
The danger of trading AN2 Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AN2 Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AN2 Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AN2 Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.